

**DRAFT
TOXICOLOGICAL PROFILE FOR
URANIUM**

**PUBLIC COMMENT PERIOD ENDS:
JULY 29, 2011**

May 2011

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

UPDATE STATEMENT

A Toxicological Profile for Uranium was released in 1999. This present edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
1600 Clifton Road NE
Mailstop F-62
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
Applied Toxicology Branch

Regular Mailing Address:
1600 Clifton Road, N.E.
Mail Stop F-62
Atlanta, Georgia 30333

Physical Mailing Address:
4770 Buford Highway
Building 106, 8th floor, MS F-62
Chamblee, Georgia 30341

Electronic Comments may be submitted via: www.regulations.gov.
Follow the on-line instructions for submitting comments identified by Docket ID No. CDC-2011-0005.

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher J. Portier, Ph.D.
Assistant Administrator
Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

- Section 1.6 How Can (Chemical X) Affect Children?**
- Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?**
- Section 3.7 Children's Susceptibility**
- Section 6.6 Exposures of Children**

Other Sections of Interest:

- Section 3.8 Biomarkers of Exposure and Effect**
 - Section 3.11 Methods for Reducing Toxic Effects**
-

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) **Fax:** (770) 488-4178
E-mail: cdcinfo@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. Department of Energy, the World Health Organization, and the International Atomic Energy Agency in the medical management of radiation accidents. A 24-hour emergency response program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, consults, or assists in the response to all kinds of radiation accidents. Contact: Oak Ridge Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 • Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for REAC/TS) • e-mail: cooleyp@orau.gov • website (including emergency medical guidance): <http://www.orau.gov/reacts/default.htm>.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

This page is intentionally blank.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Sam Keith, M.S., CHP
Obaid Faroon, D.V.M, Ph.D.
Nickolette Roney, M.P.H.
Franco Scinicariello, M.D., M.P.H.
Sharon Wilbur, M.A.
ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

Lisa Ingberman, Ph.D., DABT
Fernando Llados, Ph.D.
Daneil Plewak, B.S.
David Wohlers, Ph.D.
Gary Diamond, Ph.D.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for uranium. The panel consisted of the following members:

1. Rudolfs K. Zalups, Ph.D., Mercer University School of Medicine, Macon, Georgia;
2. Walter W. Piegorsch, Ph.D., University of Arizona, Tucson, Arizona;
3. Fletcher F. Hahn, DVM, Ph.D., DACVP, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.

These experts collectively have knowledge of uranium and uranium compound's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS.....	xii
PEER REVIEW	xiii
CONTENTS.....	xv
LIST OF FIGURES	xix
LIST OF TABLES	xxi
 1. PUBLIC HEALTH STATEMENT.....	1
1.1 WHAT IS URANIUM?.....	2
1.2 WHAT HAPPENS TO URANIUM WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO URANIUM?.....	3
1.4 HOW CAN URANIUM ENTER AND LEAVE MY BODY?.....	4
1.5 HOW CAN URANIUM AFFECT MY HEALTH?.....	5
1.6 HOW CAN URANIUM AFFECT CHILDREN?	6
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO URANIUM?	7
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO URANIUM?.....	7
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	8
1.10 WHERE CAN I GET MORE INFORMATION?	9
 2. RELEVANCE TO PUBLIC HEALTH	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO URANIUM IN THE UNITED STATES	11
2.2 SUMMARY OF HEALTH EFFECTS.....	13
2.3 MINIMAL RISK LEVELS (MRLs)	18
 3. HEALTH EFFECTS	37
3.1 INTRODUCTION.....	37
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	39
3.2.1 Inhalation Exposure	40
3.2.1.1 Death.....	41
3.2.1.2 Systemic Effects.....	44
3.2.1.3 Immunological and Lymphoreticular Effects	98
3.2.1.4 Neurological Effects	99
3.2.1.5 Reproductive Effects.....	101
3.2.1.6 Developmental Effects.....	101
3.2.1.7 Cancer	103
3.2.2 Oral Exposure.....	107
3.2.2.1 Death.....	108
3.2.2.2 Systemic Effects.....	109
3.2.2.3 Immunological and Lymphoreticular Effects	146
3.2.2.4 Neurological Effects	147
3.2.2.5 Reproductive Effects.....	150
3.2.2.6 Developmental Effects.....	153
3.2.2.7 Cancer	155

3.2.3 Dermal Exposure.....	157
3.2.3.1 Death.....	157
3.2.3.2 Systemic Effects.....	158
3.2.3.3 Immunological and Lymphoreticular Effects	169
3.2.3.4 Neurological Effects	169
3.2.3.5 Reproductive Effects.....	169
3.2.3.6 Developmental Effects.....	169
3.2.3.7 Cancer	169
3.2.4 Other Routes of Exposure	170
3.3 GENOTOXICITY	178
3.4 TOXICOKINETICS.....	185
3.4.1 Absorption.....	186
3.4.1.1 Inhalation Exposure	186
3.4.1.2 Oral Exposure	188
3.4.1.3 Dermal Exposure	189
3.4.2 Distribution	190
3.4.2.1 Inhalation Exposure	190
3.4.2.2 Oral Exposure	193
3.4.2.3 Dermal Exposure	196
3.4.2.4 Other Routes of Exposure.....	197
3.4.3 Metabolism.....	197
3.4.4 Elimination and Excretion.....	198
3.4.4.1 Inhalation Exposure	198
3.4.4.2 Oral Exposure	201
3.4.4.3 Dermal Exposure	202
3.4.4.4 Other Routes of Exposure.....	202
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	202
3.5 MECHANISMS OF ACTION	224
3.5.1 Pharmacokinetic Mechanisms.....	224
3.5.2 Mechanisms of Toxicity.....	225
3.5.3 Animal-to-Human Extrapolations	228
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	228
3.7 CHILDREN'S SUSCEPTIBILITY	230
3.8 BIOMARKERS OF EXPOSURE AND EFFECT	233
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Uranium	234
3.8.2 Biomarkers Used to Characterize Effects Caused by Uranium.....	235
3.9 INTERACTIONS WITH OTHER CHEMICALS	236
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	236
3.11 METHODS FOR REDUCING TOXIC EFFECTS.....	237
3.11.1 Reducing Peak Absorption Following Exposure.....	237
3.11.2 Reducing Body Burden	238
3.11.3 Interfering with the Mechanism of Action for Toxic Effects	239
3.12 ADEQUACY OF THE DATABASE	239
3.12.1 Existing Information on Health Effects of Uranium	240
3.12.2 Identification of Data Needs.....	242
3.12.3 Ongoing Studies	252
4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION.....	253
4.1 CHEMICAL IDENTITY.....	253
4.2 PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES	253

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	263
5.1 PRODUCTION	263
5.2 IMPORT/EXPORT	270
5.3 USE	270
5.4 DISPOSAL	274
6. POTENTIAL FOR HUMAN EXPOSURE	277
6.1 OVERVIEW.....	277
6.2 RELEASES TO THE ENVIRONMENT.....	281
6.2.1 Air	282
6.2.2 Water.....	287
6.2.3 Soil	289
6.3 ENVIRONMENTAL FATE	291
6.3.1 Transport and Partitioning.....	291
6.3.2 Transformation and Degradation	296
6.3.2.1 Air	296
6.3.2.2 Water.....	297
6.3.2.3 Sediment and Soil	297
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	298
6.4.1 Air	298
6.4.2 Water.....	299
6.4.3 Sediment and Soil	309
6.4.4 Other Environmental Media.....	311
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	311
6.6 EXPOSURES OF CHILDREN	320
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	322
6.8 ADEQUACY OF THE DATABASE	323
6.8.1 Identification of Data Needs	325
6.8.2 Ongoing Studies	328
7. ANALYTICAL METHODS	329
7.1 BIOLOGICAL MATERIALS.....	329
7.1.1 Internal Uranium Measurements.....	332
7.1.2 External Measurements	333
7.2 ENVIRONMENTAL SAMPLES	334
7.2.1 Field Measurements of Uranium.....	335
7.2.2 Collection of Environmental Samples.....	336
7.2.3 Laboratory Analysis of Environmental Samples.....	337
7.3 ADEQUACY OF THE DATABASE	344
7.3.1 Identification of Data Needs	344
7.3.2 Ongoing Studies	347
8. REGULATIONS, ADVISORIES, AND GUIDELINES.....	349
9. REFERENCES	365
10. GLOSSARY	431

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B. USER'S GUIDE.....	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1
D. OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, AND BIOLOGY	D-1
E. INDEX.....	E-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to Uranium – Inhalation	73
3-2. Levels of Significant Exposure to Uranium – Oral	128
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	204
3-4. Respiratory Tract Compartments in Which Particles May be Deposited.....	207
3-5. Environmental Pathways for Potential Human Health Effects from Uranium.....	209
3-6. The Human Respiratory Tract Model: Absorption into Blood.....	214
3-7. Structure of the Human Alimentary Tract Model (HATM)	216
3-8. Biokinetic Model for Uranium after Uptake to Blood.....	217
3-9. Multicompartmental Model for Uranium after Uptake to Blood.....	220
3-10. Multicompartmental Model	221
3-11. Existing Information on Health Effects of Uranium	241
5-1. Uranium Ore Processing.....	266
6-1. Frequency of NPL Sites with Uranium Contamination.....	278
6-2. Major DOE Offices, Facilities, and Laboratories	285
6-3. Environmental Pathways for Potential Human Health Effects from Uranium.....	292
6-4. Average Uranium Concentrations in Drinking Water for States Where Concentration Exceeds 1 pCi/L	304

This page is intentionally blank.

LIST OF TABLES

2-1. Enriched, Natural, and Depleted Uranium Mass Equivalents for Radiological Effects	20
2-2. Renal Effects Following Intermediate-Duration Inhalation Exposure to Insoluble Uranium Compounds	24
2-3. Renal Effects Following Intermediate-Duration Inhalation Exposure to Soluble and Poorly Soluble Uranium Compounds.....	26
3-1. Levels of Significant Exposure to Uranium – Inhalation	45
3-2. Levels of Significant Exposure to Uranium – Oral	110
3-3. Levels of Significant Exposure to Uranium – Dermal	159
3-4. Summary of Significant Observations in Studies of a Cohort of Gulf War Veterans Exposed to Depleted Uranium.....	171
3-5. Genotoxicity of Uranium <i>In Vivo</i>	181
3-6. Genotoxicity of Uranium <i>In Vitro</i>	183
3-7. Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity	208
3-8. Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract	210
3-9. Sensitivity and Calculated Transfer Coefficients (d^{-1}).....	223
4-1. Chemical Identity of Uranium Metal.....	254
4-2. Physical and Chemical Properties of Selected Uranium Compounds	255
4-3. Percent Occurrence and Radioactive Properties of Naturally Occurring Isotopes of Uranium.....	258
4-4. ^{238}U Decay Series Showing Sources and Decay Products	259
5-1. Uranium Ores	264
5-2. Uranium Production in the United States by Uranium Mills and Other Sources	268
5-3. Uranium Mining Production, 1985–2009	269
5-4. Import of Uranium and Compounds (in kg) into the United States (1990–1998)	271
5-5. Export of Uranium and Compounds (in kg) (1990–1998)	272

5-6. Foreign Purchases and Foreign Sales of Uranium (kg U ₃ O ₈ Equivalent) by U.S. Suppliers and Owners and Operators of U.S. Civilian Nuclear Power Reactors, 1994–2009.....	273
6-1. Normalized Uranium Effluent Discharges from Uranium Mining, Milling, Conversion, Enrichment, and Fuel Fabrication.....	283
6-2. Uranium in Airborne Particles (Composites)	300
6-3. Uranium in Drinking Water (Composites)	305
6-4. Uranium Analyses of Select Precipitation Composite Samples March–May 1996.....	306
6-5. Uranium in Rocks and Soils	310
6-6. Concentrations of Uranium in Some Foods.....	312
6-7. Geometric Mean and Selected Percentile of Urinary Concentrations of Uranium ($\mu\text{g/g}$ Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES)	315
6-8. Geometric Mean and Selected Percentile of Urinary Concentrations of Uranium ($\mu\text{g/L}$) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES)	317
6-9. Urinary Levels of Uranium in Individuals Exposed through Military Use of Depleted Uranium ...	324
7-1. Analytical Methods for Determining Uranium in Biological Samples	330
7-2. Analytical Methods for Determining Uranium in Environmental Samples	338
7-3. Additional Analytical Methods for Determining Uranium in Environmental Samples	345
8-1. Regulations and Guidelines Applicable to Uranium	350